[{"orgOrder":0,"company":"Comet Therapeutics","sponsor":"VectivBio","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Acquisition","leadProduct":"VB-1197","moa":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Comet Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Comet Therapeutics \/ VectivBio Holding","highestDevelopmentStatusID":"4","companyTruncated":"Comet Therapeutics \/ VectivBio Holding"}]

Find Clinical Drug Pipeline Developments & Deals by Comet Therapeutics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Antibody Engineering
                          Not Confirmed
                          Antibody Engineering
                          Not Confirmed

                          Details : The acquisition of the CoMET platform significantly enhances and expands VectivBio’s pipeline including VB-1197, being evaluated in methylmalonic acidemia (MMA) and propionic acidemia (PA), two organic acidemias result in severe neurological disability...

                          Brand Name : VB-1197

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          September 21, 2021

                          Lead Product(s) : VB-1197

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Preclinical

                          Sponsor : VectivBio

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank